<DOC>
	<DOCNO>NCT01757782</DOCNO>
	<brief_summary>The purpose study study role oral Sildenafil Persistent Pulmonary Hypertension Newborn ( PPHN ) secondary Meconium Aspiration Syndrome ( MAS ) newborns study risk factor MAS develop PPHN .</brief_summary>
	<brief_title>Oral Sildenafil Persistent Pulmonary Hypertension Secondary Meconium Aspiration Syndrome Newborns</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Meconium Aspiration Syndrome</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Newborns diagnose MAS two follow three criterion present . ( 1 ) Meconium stain liquor stain umbilical cord skin nail . ( 2 ) Respiratory distress , within one hour birth . ( 3 ) Radiological evidence aspiration pneumonitis ( atelectasis and/or hyperinflation ) . Newborns MAS diagnose clinical PPHN enrol study drug trial . PPHN determine either clinically loud P2 ( second component second heart sound ) , 10 % great pre/post ductal difference arterial oxygenation ( obtain acid base gas analysis ) upper limb lower limb SpO2 difference ( obtain pulse oximetry ) . ( ) baby congenital heart disease ( b ) congenital anomaly particularly incompatible life cause respiratory distress e.g . diaphragmatic hernia ( c ) Respiratory morbidity hyaline membrane disease , congenital pneumonia ( ) Babies PPHN secondary MAS admit 12 hour delivery ( e ) Non availability consent guardian interventional procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Hours</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>